The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4.
本发明涉及新型三
氟甲基-噁二唑衍
生物的公式(I),以及其药学上可接受的盐,其中所有变量均如规范中所定义,其制药组合物,药物组合物,以及它们作为药物的用途,特别是通过抑制H
DAC4治疗神经退行性,肌肉萎缩或代谢综合症。